Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5972 | (+)-Taxifolin |
| (+)-Taxifolin is an inhibitor of aggregation of the 42-residue amyloid β-protein, it has preventive effects against Alzheimer's disease-like pathogenesis in vivo. It is also a weak inhibitor of cytochrome b5 reduction (IC50=9.8μM). | |
| BCN5986 | Celastrol |
| Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol is also a novel HSP90 inhibitor, it has anti-proliferative, anti-inflammatory, anti-tumor , antiangiogenesis, and antioxidant activities. Celastrol inhibits Plasmodium falciparum enoyl-acyl carrier protein reductase and inhibits VEGF receptors expression. | |
| BCN5988 | Hypaconitine |
| Hypaconitine, an active and highly toxic constituent derived from Aconitum species, has anti-inflammatory activity, is widely used to treat rheumatism. It produced neuromuscular blockade by reducing the evoked quantal release, the mechanism of this effect was attributed mainly to blocking of the nerve compound action potential. | |
| BCN5995 | Squalene |
| Squalene, a naturally occurring substance found in plants, animals and humans, is a component of some adjuvants that is added to vaccines to enhance the immune response.Squalene shows several pharmacological properties such as hypolipidemic, hepatoprotective, cardioprotective, antioxidant, and antitoxicant activity. Squalene can significantly suppress colonic aberrant crypt foci (ACF) formation and crypt multiplicity strengthens the hypothesis that squalene possesses chemopreventive activity against colon carcinogenesis. | |
| BCN6000 | Adenanthin |
| 1. Adenanthin has bacteriostatic activity. 2. Adenanthin has antiinflammatory activity. 3. Adenanthin has antitumour activity . 4. Adenanthin is a novel NF-κB and nucleophilic cysteines inhibitor. 5. Adenanthin has antileukemic activity through targeting peroxiredoxin I/II. 6. Adenanthin can serve as the development of Prx I– and Prx II–targeted therapeutic agents. | |
